A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
Price : $35 *
At a glance
- Drugs AGN 195263 (Primary)
- Indications Meibomianitis
- Focus Therapeutic Use
- Sponsors Allergan
- 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Planned End Date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 20 Oct 2014 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.